One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation
|
|
- Griselda Parks
- 6 years ago
- Views:
Transcription
1 One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation Charles R. Cunningham* and Kurt A. Fegely Two aqueous enteric coating systems, poly(vinyl acetate) phthalate based Sureteric and acrylicbased Acryl-Eze, were evaluated for coating performance on acetylsalicylic acid 81-mg tablets. Both systems provided acceptable acid resistance at coating weight gains as low as 6%, which were achieved in as little as 1.9 h for a 130-kg batch size. Tablets coated with each system out-performed the USP requirements for dissolution and free salicylic acid levels initially and after three months storage at 40 C and 75% RH. PHOTODISC, INC. Aqueous enteric coating systems have been widely used for many years and offer substantial advantages over solvent systems, particularly with regard to environmental and toxicological concerns. Although these formulated aqueous enteric coating systems were an advancement from traditional solvent systems, they required the separate addition of plasticizers, detackifiers, pigments, and other process aids (1). Through the years, little reduction has taken place in the complexity of these systems (2). Selection of the optimal additives for each formulation adds time to the development of individual formulations (3 5). Multiple, time-consuming steps also are required in the preparation of these aqueous enteric coating dispersions (6). In addition, many of these systems are provided as liquid dispersions, which can be problematic when handling, transporting, and controlling storage conditions. Two fully formulated, aqueous enteric coating systems now are commercially available. The systems are based on two different acid-insoluble polymers. The Sureteric system is based on poly(vinyl acetate) phthalate (PVAP), and the Acryl-Eze system is based on methacrylic acid copolymer type C (Eudragit L100-55, Röhm GmbH, Darmstadt, Germany). Both systems are dry dispersible powders that do not require the use of any additional plasticizers, detackifiers, or neutralization agents. This study evaluated both systems for ease of use and acid resistance characteristics in the production-scale film coating of acetylsalicylic acid (ASA) 81-mg tablets. Charles R. Cunningham is a global technical manager in global technical support, and Kurt A. Fegely is group leader in new product development, both at Colorcon, 415 Moyer Blvd., West Point, PA 19486, tel , fax *To whom all correspondence should be addressed. Materials and equipment The tablet formulation contained ASA 40-mesh crystals (aspirin 1040, Rhodia, Cranbury, NJ), partially pregelatinized corn starch (Starch 1500, Colorcon, West Point, PA), microcrystalline cellulose (Emcocel 50M, Penwest, Patterson, NY), and stearic acid NF (purified vegetable-grade powder, Oleotec Ltd., London, UK). The tablet ingredients were dry blended in a 40-ft 3 twin-shell blender (Patterson-Kelley Co., East Stroudsburg, PA). Tablets were compressed on a 30-station rotary press (Type B4, Manesty, Liverpool, UK) using 7-mm standard concave type B tooling (Natoli Engineering Co., St. Charles, MO). Tablet hardness and weight variation were measured using a Multichek tester (Erweka, Milford, CT). 36 Pharmaceutical Technology NOVEMBER
2 Table I: Composition of the coating dispersions. Component % Weight (kg) % Weight (kg) Coating solids Deionized water Total * * 65.0 g of antifoam emulsion was added to the water before the acrylic powder. Table II: Uncoated ASA 81-mg tablet properties. Test Average Standard Deviation Weight (mg) n Breaking force (kp) n Friability (%) 20 tablets 0.12 Disintegration time in water (min) n Table III: Mixing time comparison (in minutes). Mixing Step Antifoam addition 0.5 Enteric powder addition Mixing before coating Filtration through screen Total dispersion preparation time Table IV: Coating process conditions. Process Parameter PVAP-Based Acrylic-Based Average inlet temperature ( C) Average exhaust temperature ( C) Average tablet-bed temperature ( C) Average spray rate (g/min) Atomizing air pressure (bar) Fan air pressure (bar) Pan speed (rpm) Airflow (m 3 /h) Total spray time (min) The coating materials used were the PVAP-based white aqueous enteric coating system (Sureteric) and the methacrylic acid copolymer (acrylic) based pigmented aqueous enteric film coating system (Acryl-Eze), both manufactured by Colorcon. An antifoaming agent (30% simethicone emulsion USP, Dow Chemical Co., Midland, MI) was used in the preparation of the acrylic-based system. The PVAP-based dispersion was prepared using a model RW 28 DX mixer (IKA Labortechnik, Staufen, Germany). A model AX3 mixer (Silverson Machines Ltd., Chesham Bucks, UK) was used to prepare the acrylic-based dispersion. Early mixing guidelines for the acrylic-based product recommended the use of a high-shear mixer such as the AX3. Subsequent technical literature indicates that either high- or low-shear mixing can be used for preparing the coating dispersion (7). A side-vented 48-in. coating pan (Accelacota 150, Manesty, Liverpool, UK) was used to apply the coatings. Acid uptake testing was performed using a disintegration-testing apparatus (model ZT54, Erweka, Milford, CT). An automated dissolution test station (VK- 7010, apparatus I, VanKel, Cary, NC) with a UV spectrophotometer (Varian, Palo Alto, CA) was used for drug-release testing. An HPLC system (Alliance 2690, Waters Corp., Milford, MA) was used for free salicylic acid determinations. The packaging materials used for stability testing of the coated tablets were 85-cm 3 foil sealable HDPE bottles (Drug Plastics and Glass Co., Boyertown, PA) and desiccant packs (3964, Süd-Chemie Performance Packaging, Belen, NM). Methods Blending and tablet preparation. ASA, microcrystalline cellulose, partially pregelatinized starch, and stearic acid were blended for 20 min in the twin-shell blender. The batch size was 560 kg. The blend was compressed to a target tablet weight of 170 mg, and the compaction force was adjusted to produce tablets with a breaking force of 8 kp and 0.25% friability. Press speed was 42 rpm for a production rate of 75,600 tablets/h. Preparation of the coating dispersions. Coating dispersions were prepared by adding the dry aqueous enteric coating formulations directly into a mixing tank filled with deionized water (ambient ~20 C). Mixer speed was controlled to produce and maintain a deep center liquid vortex into which the powder was added. For the acrylic-based system, antifoam was added to the water just before the addition of the powder to reduce foam generated during the initial high-speed mixing. Immediately after the addition of the powder to the water, the mixer speeds were reduced to maintain gentle stirring. This was done for both coating polymer systems. The coating systems were dispersed at the solids concentration recommended by the manufacturer. A sufficient amount of each coating dispersion was prepared to apply a theoretical 10% weight gain of coating to the tablets (see Table I). Each of the dispersions was screened through a 250- m sieve before coating. Spray coating. Tablet coating was carried out in the 48-in. sidevented pan equipped with four spray guns. The coating dispersions were delivered to the spray guns through individual tubes fed from a peristaltic pump. The pan load of ASA 81-mg tablets was 130 kg. The coating process controls were set using the parameters recommended by the manufacturer for the enteric coating systems. Samples of tablets for performance testing were removed from the coating pan at increments from 5 10% theoretical coating weight gain. Process data were recorded throughout the trials. Acid uptake testing. A variation of the gastro-resistant tablet disintegration method (European Pharmacopoeia Third Edition 2001) was used. In this revised method, six coated tablets were weighed individually and placed in the disintegration basket tubes. We immersed the disintegration basket in 900 ml of 38 Pharmaceutical Technology NOVEMBER
3 0.1 N hydrochloric acid and operated the apparatus for 2 h. The individual tablets that were still intact then were dried with a towel and reweighed. The percent of weight increase was reported as % acid uptake. Tablets that fully disintegrated during the testing were counted as having 100% acid uptake. This method has been reported to provide an accurate measure of acid resistance of the coating, and acid uptake values 5% suggest that the tablets would readily pass the acid phase of the delayed-release dissolution testing (8). Dissolution and free salicylic acid testing. The dissolution and free salicylic acid tests for the coated tablets were performed according to the USP 24 monograph for delayed-release ASA tablets. Packaging and stability. Two sets of coated tablets from each trial were packaged in high-density polyethylene (HDPE) bottles (120 tablets/bottle). One set was packaged with desiccant and the other without. All bottles were induction (foil) sealed and placed in a chamber for three months at 40 C and 75% RH. Results and discussion Uncoated aspirin tablets. Tablets used in a functional coating process must be sufficiently robust to withstand mechanical stresses and to exhibit very low potential for erosion and edge chipping. Any defects in the tablet core may result in a localized weakness of the functional film. A subcoating process may be used to strengthen friable cores before the application of the Table V: Dissolution results. % Released in t 80% in % Released in t 80% in Theoretical 0.1 N HCL Phosphate Buffer 0.1 N HCL Phosphate Buffer Weight Gain (%) after 2 h (ph 6.8) after 2 h (ph 6.8) min min min min min min min min min min Table VI: Dissolution stability. % Released in t 80% in % Released in t 80% in Theoretical 0.1 N HCL Phosphate Buffer 0.1 N HCL Phosphate Buffer Weight Gain (%) after 2 h (ph 6.8) after 2 h (ph 6.8) Packaged without Desiccant 6 25 not tested min min min min min min min min min Packaged with Desiccant min min min min min min min min min min functional coat but is not desirable in terms of process time and complexity. Subcoats also may be necessary to prevent interaction between the drug substance and the coating formulation ingredients. Interactions between the ASA and either of the enteric coating systems in this study were not expected. In this study, the ASA 81-mg tablets were sufficiently robust to avoid the use of a subcoat step (See Table II). Dispersion mixing time. Because both polymer systems are fully formulated, the mixing process consisted of a simple addition of the powder formulations to the water. The total preparation time was very short for both systems (see Table III). Filtration of the material before coating was performed to ensure that no undispersed particles of polymer remained that could result in gun blockages. Coating process. The coating process for each trial was conducted using the recommended coating conditions for each coating system (9,10). The gun-to-bed distance was 24 cm, and the distance between guns was 18 cm. The spray applications were continuous from start to finish, and spray rates were held constant throughout the coating trials. The coating data are listed in Table IV. The acrylic-based system required a lower tablet-bed temperature than did the PVAP system, and the spray rate for the acrylic-based system was slightly lower. The total coating time for the acrylic-based system was shorter because of the higher solids concentration of the dispersion. The tablets were not dried further after the application of the coatings other than during a cooldown period in the pan before unloading. Coating process efficiency for both systems was 90% on the basis of the calculation of tablet-weight difference before and after coating. The coating process for both systems was free of any problems. The coated tablets had no obvious defects or signs of sticking or tackiness (see Figure 1). Acid resistance testing. Samples of the 40 Pharmaceutical Technology NOVEMBER (a) (b) Figure 1: Photographs of coated tablets (theoretical 10% weight gain). Tablets are coated with (a) the acrylic-based system and (b) the PVAPbased system.
4 % Acid uptake % Enteric coating theoretical weight gain Figure 2: Acid uptake comparison. % Acid uptake % Free salicylic acid % Theoretical coating level PVAP-based Acrylic-based PVAP-based with desiccant Acrylic-based with desiccant Figure 4: Free salicylic acid stability. PVAP-based Acrylic-based PVAP-based Acrylic-based Total coating time (h) Figure 3: Acid-resistance testing versus coating process time. tablets that were taken throughout the coating process were subjected to acid uptake testing as a measure of the necessary level of coating that would provide acceptable acid resistance. At 5% theoretical weight gain, the PVAP system exhibited less acid uptake than did the acrylic system, although both samples were well above the desired level of 5% acid uptake. Samples taken at weight gains of 6% and above all had acid uptake values of 4%. At 6% weight gain, the differences in acid uptake between the PVAP- and the acrylic-based systems did not exceed 0.63% (see Figure 2). Of concern in any coating process is the actual production time required to coat the tablets. As a batch operation, film coating is often a bottleneck in the manufacturing process. Long coating times are common for functional coatings because of the high amount of coating that must be applied as well as the need to ensure acid resistance. In the case of each enteric coating system tested in this study, the high solids concentrations and high spray rates enabled acceptable acid resistance in a relatively short time. The coating time needed to reach an acceptable level of acid resistance was 1.9 h for the acrylic-based system and 2.3 h for the PVAP-based system (see Figure 3). Dissolution testing confirmed that each system outperformed the USP requirements of 10% of ASA released in acid after 2 h and 80% released in ph 6.8 phosphate buffer within 90 min (see Table V). The USP limit for free salicylic acid in coated ASA tablets is 3.0%. It is critical to confirm that the humidity conditions and elevated temperatures in the coating process have not contributed to the degradation of the ASA. Samples taken from each trial at 6% and 10% (theoretical) weight gain had free salicylic acid levels of 0.16%. Coated-tablet stability. Dissolution and free salicylic acid content testing was conducted on the coated tablet samples after three months of storage at 40 C and 75% RH. The tablets were packaged both with and without desiccant packs as is seen in commercially available ASA products. The dissolution test results for the acrylic-coated tablet samples were virtually unchanged from the initial time point and passed USP delayedrelease requirements. The tablet samples coated with the PVAP-based system also passed the USP requirements except for the 6% weight gain sample with no desiccant in the package. The percent of ASA released in the acid phase was slightly higher overall with the PVAP system coated tablets but still well within the USP specification of 10% release (see Table VI). All tablet samples coated with either enteric coating system passed the requirements of 3% free salicylic acid. For the samples packaged without desiccant packages, the acrylic-based system had slightly higher free salicylic acid values. The addition of the desiccant packages resulted in lower free salicylic acid values (see Figure 4). Differences in the coating process conditions may explain the variation in free salicylic acid levels between the acrylic- and PVAPbased systems. Because acrylic-based systems coat at lower process temperatures, care must be taken to ensure that moisture is not absorbed by the tablet core during the coating process. Conclusion Optimum levels of enteric coating for the ASA 81-mg tablet were determined. Both fully formulated enteric coating systems, 42 Pharmaceutical Technology NOVEMBER
5 based on two different polymers, were comparable in overall process and acid resistance. Although traditional aqueous enteric coating systems can require multiple component mixing steps before coating, these systems were dispersed in one step in a minimum amount of time. Each system provided acceptable acid resistance to the ASA tablets at low weight gains and high application rates. The acrylic-based system offers the additional advantage of being fully pigmented, eliminating the need for an additional color application if a colored tablet is desired. Both systems also provided good stability in adverse storage conditions in this moisture-sensitive application. Acknowledgments The authors gratefully acknowledge James Taylor and Scott McBain of Colorcon for their help in the manufacture and coating of the ASA tablets. In addition, we thank David Ferrizzi, Laura Scattergood, and Buffy Young of Colorcon for their analytical support. Circle/eINFO 34 References 1. K. Lehmann, The Application and Processing of Acrylic Coatings in the Form of Aqueous Dispersions Compared with Organic Solutions, Acta Pharm. Fenn. 91, (1982). 2. C. Signorino, Aqueous Enteric Coating, Pharm. Technol. Tableting & Granulation Yearbook (1999). 3. N.A. Muhammad et al., Modifying the Release Properties of Eudragit L30D, Drug Dev. Ind. Pharm. 17 (18), (1991). 4. R. Bianchini, M. Resciniti, and C. Vecchio, Technological Evaluation of Aqueous Enteric Coating Systems with and without Insoluble Additives, Drug Dev. Ind. Pharm. 17 (13), (1991). 5. H. Erdmann et al., Suitability of Additives to Reduce the Tack of Kollicoat Coatings, in Proceedings of International Symposium of Controlled Release Bioactive Material (Controlled Release Society, Minneapolis, MN), 27 (2000). 6. C. Dangel et al., Aqueous Enteric Coatings with Methacrylic Acid Copolymer Type C on Basic and Acidic Drugs in Tablets and Pellets, Part 1: Acetylsalicylic Acid Tablets and Crystals, Pharm. Technol. 24 (3), (2000). 7. Acryl-Eze Preparation and Use Guidelines, technical information, Colorcon Limited, West Point, PA. 8. M.P. Jordan, J. Taylor, and P.J. Hadfield, A Comparison of the Performance Characteristics of Enteric Film Coating Systems, contributed paper presented at AAPS National Meeting, New Orleans, LA, October (1999). 9. Coating Aspirin with Sureteric in a 48-in. Accela-Cota, technical information, Colorcon, West Point, PA. 10. Acryl-Eze Coating Parameters, technical information, Colorcon, West Point, PA. PT Circle/eINFO Pharmaceutical Technology NOVEMBER
Formulation of Acetylsalicylic Acid Tablets for Aqueous Enteric Film Coating
Formulation of cetylsalicylic cid Tablets for queous Enteric Film Coating Charles R. Cunningham,* Bruce R. Kinsey, and Laura K. Scattergood COLORCON The goal of this study was to determine which combination
More informationInvestigation of a New Coating Process for the Application of Enteric Coatings to Small Tablet Samples
ACRYL-EZE Application Data Aqueous Acrylic Enteric System Investigation of a New Coating Process for the Application of Enteric Coatings to Small Tablet Samples INTRODUCTION The purpose of this study was
More informationPreparation of Robust, Enteric Coated Dosage Forms Utilizing Acryl-EZE and Aluminum Lake-Based Pigments
ACRYL-EZE Application Data Aqueous Acrylic Enteric System Preparation of Robust, Enteric Coated Dosage Forms Utilizing Acryl-EZE and Aluminum Lake-Based Pigments OBJECTIVES To prepare a one-step, aluminium
More informationInvestigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices
METHOCEL Application Data Partially Pregelatinized Maize Starch Investigation of a Venlafaxine HCl (37.5 mg) Extended Release Formulation Using Hypromellose (HPMC) Matrices ABSTRACT SUMMARY The aim of
More informationCHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION
CHAPTER 8: SOLID DOSAGE FORM COATING TECHNOLOGY NOOR MUHAMMAD SYAHRIN BIN YAHYA INTRODUCTION INTRODUCTION Coating technology is used extensively in the pharmaceutical industry, e.g. for the application
More informationInvestigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices
Surelease Application Data Aqueous Ethylcellulose Dispersion Investigation of Aqueous Ethylcellulose Dispersion in Extended Release Metformin Inert Matrices ABSTRACT SUMMARY: In the present study, Surelease,
More informationTable 1. Coating Process Conditions Used to Apply Enteric Coating. Parameter Trial 1 Trial 2 Trial 3. O'Hara LabCoat IIX (19" pan insert)
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-100 Page 1 of 6 Delayed-release Diclofenac Sodium Tablets: Scaling Up the Coating Process Bradley Beissner; Stuart C. Porter; Jeffrey
More informationPharma Ingredients & Services. Kollicoat IR White. Technical Information
Technical Information Kollicoat IR White August 2008 Supersedes issue dated June 2008 EMP 040901e-10/Page 1 of 12 = Registered trademark of BASF SE Ready-to-use coating for instant-release dosage forms
More informationMethacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 per cent (e.g. Kollicoat MAE 30 DP)
Investigating the effect of partial neutralisation of the polymer on the dissolution characteristics of poly(methacrylic acid-co-ethyl acrylate) based coats Carolina Corell 1,3 ; Florian Bang 1 ; Thorsten
More information* Current monograph name valid until May 1, 2017 ** New monograph name valid as of May 1, 2012, mandatory as of May 1, 2017
Technical Information EUDRAGIT L 30 D-55 Specification and Test Methods Ph. Eur. Methacrylic Acid - Ethyl Acrylate Copolymer (1:1) Dispersion 30 Per Cent USP/NF Methacrylic Acid Copolymer Dispersion -
More informationTable 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-97 Page 1 of 5 Utility of Polyplasdone crospovidone as a Superdisintegrant Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig
More informationThe Use of Klucel Pharm Hydroxypropylcellulose to Increase the Utility of Hydroxypropyl Methylcellulose in Aqueous Film Coating
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-049-1 (Supersedes PTR-049) Page 1 of 6 The Use of Klucel Pharm Hydroxypropylcellulose to Increase the Utility of Hydroxypropyl Methylcellulose
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-81 Page 1 of 5 Hot Melt Extrusion with Klucel hydroxypropylcellulose HPC for the Controlled Release of High Doses of a Highly Soluble
More informationKollidon SR: A polyvinyl acetate based excipient for DCsustained-release
Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release oral dosage forms by Dr. Bernhard Fussnegger BASF Aktiengesellschaft, Ludwigshafen Strategic Marketing Pharma Excipients Introduction
More information(12) United States Patent
(12) United States Patent Jordan USOO6495163B1 (10) Patent No.: () Date of Patent: Dec. 17, 2002 (54) MOISTURE BARRIER FILM COATING COMPOSITION, METHOD AND COATED FORM (75) Inventor: Martin Philip Jordan,
More informationOPADRY II. Application Data
OPADRY II Application Data High Performance Film Coating System Reducing Coated Tablet Defects from Laboratory through Production Scale: Performance of Hypromellose or Polyvinyl Alcohol-Based Aqueous Film
More informationApproval Application Form for Sakura Bloom Tablets
Approval Application Form for Sakura Bloom Tablets Mock-up for Columns of Manufacturing Methods and Specifications & Test Methods for Drug Products (sample description) Study project for regulatory harmonization
More informationINTRODUCTION TO INDUSTRIAL PHARMACY LAB 1
INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage
More informationcoating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies
As appeared in Tablets & Capsules April 201 coating www.tabletscapsules.com Layering an API onto tablets using a perforated-drum coater: A case study Vasant Shetty, Sameer Borate, Anuprita Landge, and
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-079 Page 1 of 5 Advantages of Hot Melt Extrusion for the Controlled Release of High Doses of Highly Soluble Actives E. Pinto, H. Yang,
More informationPharma Ingredients & Services. Ludiflash. Technical Information
Technical Information Ludiflash March 2012 Supersedes issue dated August 2011 03_070805e-03/Page 1 of 10 = Registered trademark of BASF group Excipient for fast-disintegrating oral dosage forms Direct
More informationSoluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services
Technical Information Soluplus October 2009 03_090801e-01/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 03_090801e-01 October 2009 Page 2 of 8 Soluplus 1. Introduction
More informationTable Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008)
Introduction After using pearlitol SD (200) along with avicel ph 112 the flow of the blend was improved but still not up to the mark. Weight variation was observed around (11.47%) which was not acceptable.
More informationTable 1: Coating Compositions. Layer Ingredient g Drug-binder solution
Poster Reprint Controlled Release Society July 7 Application of an Aqueous Ethylcellulose Dispersion in Multiple-Unit Pellet Systems. Viena D. Dias, Kurt Fegely, Abhijit V. Gothoskar and Ali R. Rajabi-Siahboomi
More informationNew Developments in Spray-Dried Lactose
New Developments in Spray-Dried Lactose Gerad Bolhuis, Klaas Kussendrager, and John Langridge* Recent advances in spraydrying technology have led to the production of new directly compressible lactose
More informationHydroxypropylcellulose Polymer Molecular Weight: Influence on Erodible Modified Release Matrix Systems By T. Dürig, W.W. Harcum, and R. A.
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-032-1 (Supersedes PTR-032) Page 1 of 7 Hydroxypropylcellulose Polymer Molecular Weight: Influence on Erodible Modified Release Matrix
More informationEffect of Formulation and Process Variables
Effect of Formulation and Process Variables On Matrix Erosion and Drug Release from a Multiunit Erosion Matrix of a Poorly Soluble Drug Ketan A. Mehta, M. Serpil Kislalioglu,* Wantanee Phuapradit, A. Waseem
More informationFILM COATINGS. Process Adaptability for the Perfect Finish. Productivity Enhancement and Efficiency Wide Processing Latitude Excellent Appearance
FILM COATINGS Process Adaptability for the Perfect Finish Productivity Enhancement and Efficiency Wide Processing Latitude Excellent Appearance Process Adaptability for the Perfect Finish Opadry QX, quick
More informationPharma Ingredients & Services. Ludiflash. Technical Information
Technical Information Ludiflash April 2008 Supersedes issue dated September 2007 EMP 070805e-01/Page 1 of 12 = Registered trademark of BASF SE Excipient for fast-disintegrating oral dosage forms Direct
More informationEffects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS
Acryl-EZE MP Poster Reprint Aqueous Acrylic Enteric System Effects of Core Tablet Size on the Functionality of Aqueous Delayed Release Coatings as Measured by SEM and LIBS PURPOSES The aim of this work
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Methods. Ashland Specialty Ingredients ashland.com
PHARMACEUTICAL TECHNOLOGY REPORT Ashland Specialty ashland.com PTR-96 Page 1 of 5 Utility of Polyplasdone crospovidone as a Solubilizer Quyen Schwing, Marvin Davis, Divya Tewari, Thomas Dürig Ashland Specialty,
More informationf a c t s T C C T B Tricalcium citrate as excipient for direct compression
f a c t s T C C T B Tricalcium citrate as excipient for direct compression Direct compression has gained enormous popularity in tablet manufacturing in recent times. It is seen as the most economic process
More informationAmount of individual ingredients added (g) Surelease dispersion*
Poster Reprint AAPS Annual Meeting November 27 The Influence of Hydrophilic Pore Formers on Dipyridamole Release from Aqueous Ethylcellulose Film-Coated Pellets Dasha Palmer, Hue Vuong, Marina Levina and
More informationTHE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri
THE PROCESS VALIDATION OF TABLET CONTAINING IRBESARTAN 300MG AND HYDROCHLOROTHIAZIDE 12.5mg Zamir Hussain, Baqir Shyum Naqvi & Muhammad Iqbal Nasiri Faculty of Pharmacy, Department of Pharmaceutics, Hamdard
More informationTASTE MASKING WITH COATINGS. Coating Technology 96 October 8-9, Presented by Ralph E. Pondell Corporate Secretary
96-2 TASTE MASKING WITH COATINGS Coating Technology 96 October 8-9, 1996 Presented by Ralph E. Pondell Corporate Secretary Coating Place, Inc. P.O. Box 930310 Verona, WI 53593 (608) 845-9521 When dealing
More informationFilm Coating Process Considerations for the Application of High Productivity, High Solids Concentration Film Coating Formulations
Opadry II Application Data High Productivity Film Coating System Film Coating Process Considerations for the Application of High Productivity, High Solids Concentration Film Coating Formulations PURPOSE
More informationReal-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology
Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology Authors: Piyush Patel A, Edward Godek B, Chris O Callaghan C, Dr. Ian Jones D A Colorcon, PA, USA
More informationMEETING YOUR CHALLENGES TODAY AND TOMORROW. Avicel PH BINDERS
MEETING YOUR CHALLENGES TODAY AND TOMORROW Avicel PH BINDERS FORMULA Functionality and Consistency... 02 Applications... 03 Direct compression... 03 Wet granulation... 04 Dry granulation... 04 Hard capsules...
More informationNISSO HPC for Pharmaceutical Applications
NISSO HPC for Pharmaceutical Applications Contents Introduction Features of NISSO HPC Major Application of NISSO HPC NISSO HPC Grades and Availability How to use based on Application and Features of NISSO
More informationDow Pharma Solutions. ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.
Dow Pharma Solutions ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. Improving Productivity Through Innovation ETHOCEL Polymers is the oldest trademarked brand available from The Dow Chemical
More informationOne non-numeric process related variable examined was post coating thermal (curing) treatment.
Poster Reprint AAPS Annual Meeting November 27 Identification and Influence of Critical Coating Process Parameters on Drug Release from a Fully Formulated Aqueous Ethylcellulose Dispersion Charles F. Vesey,
More informationBehavior of Uptake of Moisture by Drugs and Excipients under
Behavior of Uptake of Moisture by Drugs and Excipients under Accelerated Conditions of Temperature and Humidity in the Absence and the Presence of Light Part II: Packaged and Unpackaged Antituberculosis
More informationMalukani et al., IJPSR, 2012; Vol. 3(7): ISSN:
IJPSR (2012), Vol. 3, Issue 07 (Research Article) Received on 27 March, 2012; received in revised form 17 June, 2012; accepted 25 June, 2012 PROCESS VALIDATION OF SOTALOL HYDROCHLORIDE TABLETS J.N. Malukani*
More informationETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.
Dow Pharma Solutions ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. This document is valid at the time of distribution. Distributed 22-?-218 (UTC) Improving Productivity Through Innovation
More informationExtended-release Venlafaxine Pellets: Scaling Up the Coating Process Stuart C. Porter, Bradley Beissner and Jeffrey Williamson
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-104 Page 1 of 6 Extended-release Venlafaxine Pellets: Scaling Up the Coating Process Stuart C. Porter, Bradley Beissner and Jeffrey
More informationETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.
Dow Pharma Solutions ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient. This document is valid at the time of distribution. Distributed 7-Oct-218 (UTC) Improving Productivity Through Innovation
More informationSeamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production
Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production Abstract A study was conducted using the KOCO 25 in conjunction with the ROB 50, in order to provide insight
More informationThe Role of Polymer Excipients in Hot Melt Extrusion A Continuous Manufacturing Process
The Role of Polymer Excipients in Hot Melt Extrusion A Continuous Manufacturing Process Nigel Langley ExcipientFest May 1, 2018 Hot-Melt Extrusion A Continuous Manufacturing Process Principle of HME 2
More informationDissolution Enhancement of Haloperidol Tablets using ph Modifier and Co-Solubilizer
Human Journals Research Article June 2015 Vol.:3, Issue:3 All rights are reserved by Ruby Ujawane et al. Dissolution Enhancement of Haloperidol Tablets using ph Modifier and Co-Solubilizer Keywords: Haloperidol,
More informationTABLET COATING. Lec. 8
TABLET COATING Lec. 8 TABLET COATING PRINCIPLES History: Tab. coating starts with Rhazes (coated food) in 800s then developed by Frenches (sugar coat) in 1800s and finally Abbott marketed (film coat) in
More informationTricalcium citrate as excipient for direct compression
f a c t s T C C T B Tricalcium citrate as excipient for direct compression Introduction Direct compression has gained enormous popularity in tablet manufacturing in recent times. It is seen as the most
More informationKollicoat IR. The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms. ExcipientFest.
Kollicoat IR The application of Kollicoat IR as a Zero Peroxide Binder for use in Solid Oral Dosage Forms ExcipientFest Nigel Langley Market Need Platforms Instant & Modified Release Solubilization Skin
More informationMaximizing Roller Compaction Benefits with Proper Excipient Selection
A sponsored whitepaper. Maximizing Roller Compaction Benefits with Proper Excipient Selection By: Bernhard Fussnegger, Global Development and Technical Marketing, PVP/Coatings, Instant & Modified Release,
More informationPharma Ingredients & Services. Kollidon VA 64 Kollidon VA 64 Fine. Copovidone Ph.Eur., USP, Copolyvidone JPE. Technical Information
Technical Information June 2008 Supersedes issue dated October 2007 EMP 050602e-05/Page 1 of 16 Kollidon VA 64 Kollidon VA 64 Fine Copovidone Ph.Eur., USP, Copolyvidone JPE = Registered trademark of BASF
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationPreparation and Evaluation of Sustained Release Tablet of Cyproheptadine Hydrochloride Using Carbopol and HPMC
Received: 06-01-2013 Accepted: 26-02-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 1 2013 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION
More informationEVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS
EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS Inaugural-Dissertation zur Erlangung der Doktorwurde im Fachbereich Biologie, Chemie, Pharmazie der Freien Universitat Berlin vorgelegt von NANTHARAT
More informationKollidon VA 64. Technical Information. Copovidone Ph.Eur.
Technical Information ME 080 e (939) March 2000 (MPM) Kollidon VA 64 Copovidone Ph.Eur. Register 2 = Registered trademark of BASF Aktiengesellschaft Kollidon VA 64 is a vinylpyrrolidone-vinyl acetate copolymer
More informationDissolution Enhancement of Active Pharmaceutical Ingredients in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide
Dissolution Enhancement of Active Pharmaceutical Ingredients in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide Martial SAUCEAU 1, Tamás VIGH 2, Elisabeth RODIER 1, Zsombor NAGY
More informationPharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010
Technical Information Soluplus July 21 Supersedes issue dated May 21 3_981e-4/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 3_981e-4 July 21 Page 2 of 8 Soluplus 1. Introduction
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com REVIEW ARTICLE ON INPROCESS PROBLEMS AND EVALUATION TESTS
More informationDesign of Controlled Release Non-erodible Polymeric Matrix Tablet Using Microwave Oven-assisted Sintering Technique
Pharmaceutics Design of Controlled Release Non-erodible Polymeric Matrix Tablet Using Microwave Oven-assisted Sintering Technique Patel DM Patel BK Patel A Patel CN Department of Pharmaceutics and Pharmaceutical
More informationAN INTRODUCTION TO SPHERONIZATION (MARUMERIZATION * )
A TECHNICAL NOTE LABORATORY / PRODUCTION CALEVA (MARUMERIZATION * ) A Brief Non-Technical General Guide interchangeably. *Spheronization and marumerization, different names for the same thing. The two
More informationExcipient Development at NCL
New Reverse Enteric Polymer for Oral Dosage Forms Excipient Development at omplete Solution for Taste Masking Moisture Barrier Sustained Release Immediate Release Polymorphism Inhibition National hemical
More informationANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS
Association of South East Asian Nations (ASEAN) ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject
More informationStability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages.
Stability Report Stability profile of BIWG 98 SE tablets 40 mg Number SR 2001-01-04-01 Date Page 00. 00. 0000 1 of 133 Responsible Company Successful Pharma KG Biberach This stability report comprises
More informationPHARMACEUTICAL TECHNOLOGY REPORT. Introduction
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-036-1 (Supersedes PTR-036) Page 1 of 9 Water-Soluble Cellulose Ethers as Release Modulators for Ethylcellulose Coatings on Multiparticulates
More information7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben
7th Training School on Microencapsulation Strasbourg Februar 2015 1 Dr. Anne Ettner, Glatt Pharmaceutical Services 2 Overview 1. Introduction 2. Fluid bed equipment 3. Basics of fluid bed Wurster technology
More informationPrediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using corresponding values of components
Available online at www.sciencedirect.com International Journal of Pharmaceutics 352 (2008) 202 208 Prediction of suitable amounts of water in fluidized bed granulation of pharmaceutical formulations using
More informationUniversity of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester
University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester 2/26/2018 Industrial Pharmacy II, Dr. rer. nat. Rebaz Ali 1 Outlines Powder flow Introduction Factor affecting
More informationADVANTAGES OF MULTIPARTICULATES (PELLETS):
INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage
More informationBY ARJUN NARALA M.PHARMACY, I SEM DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY WARANGAL.
BY ARJUN NARALA M.PHARMACY, I SEM DEPARTMENT OF PHARMACEUTICS UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES KAKATIYA UNIVERSITY WARANGAL. CONTENTS Introduction Defects in Tablets Defects in sugar coated
More informationIn the normal process of developing formulations, and in the routine manufacture of tablets, various defects are observed. Sometimes, the source of
In the normal process of developing formulations, and in the routine manufacture of tablets, various defects are observed. Sometimes, the source of the problem or the defect is the formulation, the compression
More informationFormulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets
Human Journals Research Article July 2018 Vol.:12, Issue:4 All rights are reserved by S. Meena et al. Formulation and Evaluation of Telmisartan with Hydrochlorothiazide Conventional Release Tablets Keywords:
More informationScuffing Measurement Methodology and Improved Film Coating Systems
OPADRY II Application Data High Performance Film Coating System Scuffing Measurement Methodology and Improved Film Coating Systems PURPOSE Scuffing is a term used to describe coated tablet defects consisting
More informationElvacite 2823 Acrylic Resin for low VOC
Elvacite 2823 Acrylic Resin for low VOC Acrylic Resin Elvacite 2823 is a methyl methacrylate copolymer designed for use in VOC compliant coatings. Elvacite 2823 utilizes patented technology to provide
More informationValidation of the Cleaning In Place of the coating pan PERFIMA, IMA
Validation of the Cleaning In Place of the coating pan PERFIMA, IMA Author Prof. Ruggero Bettini Published in October 26 Università degli Studi di Parma, Dipartimento Farmaceutico Viale G. P. Usberti,
More informationProcess Validation of Oral Solid Dosage Form-Tablet containing Anti Tubercular Agent
Available online on www.ijpqa.com International Journal of Pharmaceutical Quality Assurance; 4(3); 27-36 Research Article ISSN 05 06 Process Validation of Oral Solid Dosage Form-Tablet containing Anti
More informationSUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593
SUSTAINED RELEASE From Coated Ion Exchange Resins 79-1 by H.S. Hall Coating Place, Inc. Verona, WI 53593 A substantial amount of work has been published concerning the use of ion exchange resins for sustained
More informationStreamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon
Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression Katie Hewlett, Dow Gus LaBella, Colorcon Controlled Release Alliance Unique Together Leading polymer expertise Quality
More informationTHE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION Pharmacopeial Forum Vol. 31(5)(Sept.-Oct. 2005) By : Mr. Seubpong Kumpusiri Mrs. Patima Maneesatid 26 May 2006 THE DISSOLUTION PROCEDURE: DEVELOPMENT
More informationDRY COATING : Techniques & Potentials
Water in Food Workshop Lausanne 2004 DRY COATING : Techniques & Potentials E. TEUNOU - E. IVANOVA - D. PONCELET Nantes Département du Génie des Procédés Alimentaire Content Who are we? Importance and Functionality
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.1, pp ,
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.1, pp 139-147, 2014-2015 Pharmaceutical Prospective Process Validation Of Chloroquiune Tablets Vilas S Jadhav*,
More informationCopyright CSC Publishing
As appeared in March 2014 roller compaction www.tabletscapsules.com Effect of roller compaction pressure on the blend and tablet properties of a formulation containing a poorly soluble drug E. E. Robles,
More informationWHOPAR. SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationFormulation Development & CTM Manufacturing Services
Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range
More informationHARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS
HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS QUALICAPS HISTORY Over one hundred years of experience in the manufacturing and filling of hard two-piece capsules Qualicaps originated within
More informationDirect Compression Microcrystalline Cellulose Grade 12 versus Classic Grade 102
Direct Compression Microcrystalline Cellulose Grade 1 versus Classic Grade 1 Masaki Hasegawa The author compared the behavior of two grades of microcrystalline cellulose during the direct-compression process.
More informationAhmed et al., Received- 5 February 2009 Accepted for Publication- 1 March, 2009
The Effect of Manufacturing Methods and Different Shapes on the Release Pattern of Diclofenac Sodium Matrix Tablet Tajnin Ahmed 1, Muhammad Shahidul Islam 2*, Tasnuva Haque 1, Mohammad Abusyed 3 1 Department
More informationPreparation of Antipyretic Analgesic by Direct Compression and Its Evaluation
1542 Chem. Pharm. Bull. 50(12) 1542 1549 (2002) Vol. 50, No. 12 Preparation of Antipyretic Analgesic by Direct Compression and Its Evaluation Keijiro TERASHITA* and Keisuke IMAMURA Osaka Prefecture University,
More informationPHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS
PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS J. T. Carstensen, Ph.D. Professor of Pharmacy University of Wisconsin Madison, Wisconsin TECHNOMIC ^PUBLISHING CO.. INC J 1.ANCASTER BASET, TABLE OF CONTENTS
More informationMETHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow
METHOCEL Cellulose Ethers A product that can do it all TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow The possibilities are endless Pharmaceutical companies are continuously
More informationComparative analysis of eight brands of sulfadoxinepyrimethamine
Tropical Journal of Pharmaceutical Research, June 2003; 2 (1): 161-167 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria. All rights reserved. Available online at http://www.tjpr.freehosting.net
More informationAsian Journal of Research in Pharmaceutical Sciences and Biotechnology
Research Article ISSN: 2349 7114 Asian Journal of Research in Pharmaceutical Sciences and Biotechnology Journal home page: www.ajrpsb.com FORMULATION DEVELOPMENT AND EVALUATION OF PANTOPRAZOLE DELAYED
More informationInternational Journal of Pharmacy
International Journal of Pharmacy Journal Homepage: http://www.pharmascholars.com Research Article CODEN: IJPNL6 FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF RANOLAZINE M Vanaja kumari
More informationTHE PHYSICAL CHARACTERISTICS OF LYOPHILIZED TABLETS CONTAINING A MODEL DRUG IN DIFFERENT CHEMICAL FORMS AND CONCENTRATIONS
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 62 No. 1 pp. 25ñ29, 2005 ISSN 0001-6837 Polish Pharmaceutical Society DRUG TECHNOLOGY THE PHYSICAL CHARACTERISTICS OF LYOPHILIZED TABLETS CONTAINING A
More information4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF. The microbiological assay was performed by using the test
109 4.4 MICROBIOLOGICAL METHOD FOR THE ESTIMATION OF AMOXICILLIN The microbiological assay was performed by using the test organism Staphylococcus aureus. The strain was isolated from soil and allowed
More informationSakura Bloom Tablets P2 Mock
Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Research Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com FORMULATION AND EVALUATION OF ESOMEPRAZOLE MAGNESIUM
More information